Innate and adaptive immune responses related to IBD pathogenesis

被引：78

作者：

Arseneau K.O. ^{[1
]}

Tamagawa H. ^{[1
]}

Pizarro T.T. ^{[1
]}

Cominelli F. ^{[1
]}

机构：

[1] Digestive Health Research Center, University of Virginia Health System, Charlottesville, VA 22908-0708

来源：

Current Gastroenterology Reports | 2007年 / 9卷 / 6期

关键词：

Ulcerative Colitis; Th17 Cell; Adaptive Immune Response; Mucosal Immune System; Physiol Gastrointest Liver;

D O I：

10.1007/s11894-007-0067-3

中图分类号：

学科分类号：

摘要：

Although the adaptive immune system traditionally has been the primary focus of investigations into the pathogenesis of inflammatory bowel disease (IBD), it is now clear that innate immune responses play an equally important, or perhaps even primary, role in disease initiation. Intestinal barrier function defects and genetic associations with the nucleotide-binding oligomerization domain and Toll-like receptor pathways suggest that the innate immune system has failed to protect the host against the vast array of commensal bacteria in the gut. This hypothesis is supported further by the observation that probiotic agents exert anti-inflammatory effects in the intestine through stimulation, rather than suppression, of the mucosal innate immune system. Moreover, it is now clear that adaptive immune responses involved in IBD pathogenesis are more complex than the traditionally dichotomous Th1/Th2 paradigm. Finally, mounting evidence suggests that the Th17 effector pathway may contribute to Crohn's disease pathogenesis. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：508 / 512

页数：4

共 43 条

[1]

Loftus Jr E.V., Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences, Gastroenterology, 126, pp. 1504-1517, (2004)

[2]

Bamias G., Nyce M.R., De La Rue S.A., Cominelli F., New concepts in the pathophysiology of inflammatory bowel disease, Ann Intern Med, 143, pp. 895-904, (2005)

[3]

Podolsky D.K., Inflammatory bowel disease, N Engl J Med, 347, pp. 417-429, (2002)

[4]

Cominelli F., Cytokine-based therapies for Crohn's disease - new paradigms, N Engl J Med, 351, pp. 2045-2048, (2004)

[5]

Powrie F., Leach M.W., Mauze S., Et al., Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice, Int Immunol, 5, pp. 1461-1471, (1993)

[6]

Kosiewicz M.M., Nast C.C., Krishnan A., Et al., Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease, J Clin Invest, 107, pp. 695-702, (2001)

[7]

Targan S.R., Hanauer S.B., van Deventer S.J., Et al., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, 337, pp. 1029-1035, (1997)

[8]

Rutgeerts P., Sandborn W.J., Feagan B.G., Et al., Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, pp. 2462-2476, (2005)

[9]

Monteleone G., Biancone L., Marasco R., Et al., Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells, Gastroenterology, 112, pp. 1169-1178, (1997)

[10]

Pizarro T.T., Michie M.H., Bentz M., Et al., IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells, J Immunol, 162, pp. 6829-6835, (1999)

← 1 2 3 4 5 →